H-Index
79
Scimago Lab
powered by Scopus
JCR
Clarivate
Analytics
16%
Acceptance
Rate
call: +1.631.470.9640
Mon-Fri 10 am - 2 pm EST

Logo

Medical Science Monitor Basic Research
AmJCaseRep

Annals
ISI-Home

eISSN: 1643-3750

Melatonin MT1 and MT2 receptor expression in Parkinson's disease

Nikhil Adi, Deborah C Mash, Yousuf Ali, Carlos Singer, Lina Shehadeh, Spyridon Papapetropoulos

Med Sci Monit 2010; 16(2): BR61-67

ID: 878353

Available online: 2010-02-01

Published: 2010-02-01


#878353

Background: Idiopathic Parkinson disease (PD) is a multi-system disorder with a multifactorial etiology and diverse clinical phenotype. Selective, regional dopaminergic neuronal degeneration in the substantia nigra and other CNS areas including the amygdala are observed in all patients. Apoptotic mechanisms resulting from oxidative stress and mitochondrial dysfunction have been implicated in the pathogenesis of the disease. Although the role of melatonin, a potent endogenous antioxidant, has been highlighted in PD there is no data on the expression of melatonin receptors in affected CNS regions.
Material and Method: We conducted an RT-PCR-based study to determine the MT1 and MT2 receptors expression in whole brain post-mortem tissue from the amygdala and substantia nigra of well-characterized PD and control subjects.
Results: PD cases showed a statistically significant decrease of MT1 receptor expression in both substantia nigra (FC=5.11; p<0.05) and the amygdala (FC=3.11; p<0.001) versus normal controls. The expression of MT2 receptor expression was also decreased in both substantia nigra (FC=3.90; p<0.0001) and the amygdala (FC=1.91; p<0.001) versus normal controls.
Conclusions: The results demonstrate a down-regulation of melatonin receptors in regions affected by PD, suggesting their possible involvement in the disease process. Future studies are needed to elucidate the role of melatonin and its receptors in the treatment/pathogenesis of PD.

Keywords: Reverse Transcriptase Polymerase Chain Reaction, Receptor, Melatonin, MT2 - metabolism, Receptor, Melatonin, MT1 - metabolism, Parkinson Disease - pathology, Down-Regulation, Cohort Studies, Case-Control Studies, Amygdala - pathology, Aged, 80 and over, Substantia Nigra - pathology



Back